Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: A case-control study

Pharmacy World and Science

Volumn 27, Issue 4, 2005, Pages 285-289

  Schillevoort, I ^a   Herings, R M C ^a   Hugenholtz, G W K ^b   De Boer, A ^a   Nolen, W A ^b,c   Roos, R A C ^d   Leufkens, H G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Willem Arntz Huis   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADRs; Antipsychotics; Atypical antipsychotics; Extrapyramidal syndromes; Parkinsonism; Schizophrenia; Side effect

Indexed keywords

ALIMEMAZINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERAZINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PIPOTIAZINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNINDEXED DRUG; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MALE; MEDICAL RECORD; MENTAL HOSPITAL; NETHERLANDS; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SYNDROME;

EID: 26844533763     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-004-5797-9     Document Type: Article

References (26)

1. CJL Murray AD. Lopez 1996 The Global Burden of Disease and Injury Series, Vol 1: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 Harvard University Press Cambridge, MA
2. Gijsen R, Roos MJC. Hoe vaak komt schizofrenie voor? In: Volksgezondheid toekomst verkenning, Nationaal kompas volksgezondheid. Bilthoven: RIVM, 2004.
3. DE. Casey 1991 Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia Schizophr Res 4 2 109 20
4. JT Schwartz AW. Brotman 1992 A clinical guide to antipsychotic drugs Drugs 44 6 981 92
5. G Chouinard 1993 A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients J Clin Psychopharmacol 13 1 25 40
6. CM Beasley Jr 1997 Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial Eur Neuropsychopharmacol 7 2 125 37
7. DL Zimbroff 1997 Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group Am J Psychiatry 154 6 782 91
8. OJ Hoyberg 1993 Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations Acta Psychiatr Scand 88 6 395 402
9. SK Min 1993 Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial Yonsei Med J 34 2 179 90
10. CH Miller 1998 The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics J Clin Psychiatry 59 2 69 75
11. PI Rosebush MF. Mazurek 1999 Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone Neurology 52 4 782 5
12. DG Standaert AB. Young 1995 Treatment of central nervous system degenerative disorders LS Goodman A Gilman JG Hardman AG Gilman LE Limbird The Pharmacological Basis of Therapeutics 9 McGraw-Hill New York 504 20
13. A. Van der Kuy 1998 Farmacotherapeutisch Kompas Centrale Medisch Farmaceutische Commissie van de Ziekenfondsraad Amstelveen
14. CF. George 1997 British National Formulary, September 1997 British Medical Association and the Royal Pharmaceutical Society of Great Britain London
15. AC Egberts 1997 Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment J Clin Psychopharmacol 17 3 149 55
16. Anonymous, Anatomical Therapeutic Chemical (ATC) 1998 Classification Index: Including Defined Daily Doses (DDD) for Plain Substances World Health Organization Oslo, Norway
17. P Bollini 1994 Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials Psychol Med 24 2 307 16
18. FJ Jimenez Jimenez PJ Garcia Ruiz JA. Molina 1997 Drug-induced movement disorders Drug Saf 16 3 180 204
19. S. Greenland 1989 Modeling and variable selection in epidemiologic analysis Am J Public Health 79 3 340 9
20. JJ. Schlesselman 1982 Case-control studies Oxford University Press New York 200 6
21. J Avorn 1995 Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study Am J Med 99 1 48 54
22. L Ganzini 1991 Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study J Geriatr Psychiatry Neurol 4 4 222 5
23. F. Ayd 1961 A survey of drug-induced extrapyramidal reactions JAMA 175 12 1055 60
24. DB Menkes 1987 Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs Int Clin Psychopharmacol 2 1 55 67
25. SR Marder RC. Meibach 1994 Risperidone in the treatment of schizophrenia Am J Psychiatry 151 6 825 35
26. KJ Rothman S. Greenland 1998 Modern Epidemiology 2 Lippincott-Raven Philadelphia